Sarepta soars as DMD therapy makes major strides but challenges lay ahead
This article was originally published in Scrip
Executive Summary
Impressive improvements in six-minute walk test (6MWT) results for Duchenne muscular dystrophy (DMD) patients at 48 weeks of treatment with the exon-skipping drug eteplirsen caused Sarepta Therapeutics' stock price to triple on the Nasdaq, as long-term Phase IIb data demonstrated the greatest efficacy for a DMD therapy to date.